Research Analysts’ price target changes for Thursday, November 5th:
Addus HomeCare (NASDAQ:ADUS) had its target price increased by TD Cowen from $131.00 to $145.00. They currently have a buy rating on the stock.
AdaptHealth (NASDAQ:AHCO) had its price target raised by Leerink Partners from $7.00 to $8.00. The firm currently has an outperform rating on the stock.
Amgen (NASDAQ:AMGN) had its price target raised by Leerink Partners from $395.00 to $464.00. The firm currently has a market perform rating on the stock.
Amneal Pharmaceuticals (NASDAQ:AMRX) had its target price increased by Leerink Partners from $23.00 to $25.00. They currently have an outperform rating on the stock.
Bruker (NASDAQ:BRKR) had its target price raised by Leerink Partners from $80.00 to $85.00. They currently have an outperform rating on the stock.
CDW (NASDAQ:CDW) had its price target boosted by Citigroup from $150.00 to $170.00. Citigroup currently has a neutral rating on the stock.
Chime Financial (NASDAQ:CHYM) had its target price raised by Scotiabank from $42.00 to $44.00. The firm currently has a sector outperform rating on the stock.
Cencora (NYSE:COR) had its price target raised by Leerink Partners from $388.00 to $405.00. They currently have an outperform rating on the stock.
Corpay (NYSE:CPAY) had its price target increased by Scotiabank from $536.00 to $539.00. Scotiabank currently has a sector outperform rating on the stock.
Circle Internet Group (NYSE:CRCL) had its target price trimmed by TD Cowen from $92.00 to $87.00. They currently have a buy rating on the stock.
CVS Health (NYSE:CVS) had its price target trimmed by Leerink Partners from $112.00 to $104.00. Leerink Partners currently has an outperform rating on the stock.
Datadog (NASDAQ:DDOG) had its target price cut by TD Cowen from $300.00 to $275.00. TD Cowen currently has a buy rating on the stock.
Datadog (NASDAQ:DDOG) had its target price lowered by Citigroup from $305.00 to $290.00. The firm currently has a buy rating on the stock.
e.l.f. Beauty (NYSE:ELF) had its price target boosted by Citigroup from $130.00 to $139.00. Citigroup currently has a buy rating on the stock.
Evolent Health (NYSE:EVH) had its price target increased by Needham & Company LLC from $5.00 to $6.00. They currently have a buy rating on the stock.
Edwards Lifesciences (NYSE:EW) had its price target raised by Citigroup from $110.00 to $117.00. Citigroup currently has a buy rating on the stock.
Exelixis (NASDAQ:EXEL) had its price target increased by Leerink Partners from $55.00 to $58.00. Leerink Partners currently has a market perform rating on the stock.
Fidelity National Information Services (NYSE:FIS) had its target price reduced by Citigroup from $39.00 to $30.00. The firm currently has a neutral rating on the stock.
Fidelity National Information Services (NYSE:FIS) had its price target lowered by TD Cowen from $47.00 to $38.00. They currently have a buy rating on the stock.
Genius Sports (NYSE:GENI) had its target price reduced by BTIG Research from $10.00 to $8.00. They currently have a buy rating on the stock.
GlobalFoundries (NASDAQ:GFS) had its price target cut by TD Cowen from $75.00 to $60.00. They currently have a buy rating on the stock.
ZoomInfo Technologies (NASDAQ:GTM) had its price target raised by Royal Bank Of Canada from $3.00 to $3.50. Royal Bank Of Canada currently has an underperform rating on the stock.
W.W. Grainger (NYSE:GWW) had its target price increased by Royal Bank Of Canada from $1,427.00 to $1,582.00. They currently have a sector perform rating on the stock.
HubSpot (NYSE:HUBS) had its price target reduced by TD Cowen from $260.00 to $215.00. They currently have a hold rating on the stock.
Incyte (NASDAQ:INCY) had its price target trimmed by Leerink Partners from $154.00 to $150.00. The firm currently has an outperform rating on the stock.
Kyndryl (NYSE:KD) had its target price increased by Scotiabank from $15.00 to $19.00. They currently have a sector perform rating on the stock.
LENZ Therapeutics (NASDAQ:LENZ) had its target price reduced by Citigroup from $10.00 to $9.00. They currently have a buy rating on the stock.
LifeStance Health Group (NASDAQ:LFST) had its price target raised by BTIG Research from $18.00 to $20.00. BTIG Research currently has a buy rating on the stock.
Lumen Technologies (NYSE:LUMN) had its target price reduced by TD Cowen from $9.00 to $8.00. They currently have a hold rating on the stock.
McDonald’s (NYSE:MCD) had its target price increased by Citigroup from $295.00 to $315.00. Citigroup currently has a buy rating on the stock.
McKesson (NYSE:MCK) had its price target increased by TD Cowen from $1,006.00 to $1,200.00. TD Cowen currently has a buy rating on the stock.
Medline (NASDAQ:MDLN) had its price target increased by Leerink Partners from $43.00 to $46.00. The firm currently has an outperform rating on the stock.
MercadoLibre (NASDAQ:MELI) had its target price reduced by Scotiabank from $2,800.00 to $2,300.00. They currently have a sector outperform rating on the stock.
Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price lowered by Leerink Partners from $154.00 to $140.00. The firm currently has an outperform rating on the stock.
MKS (NASDAQ:MKSI) had its price target reduced by Needham & Company LLC from $390.00 to $300.00. They currently have a buy rating on the stock.
Myriad Genetics (NASDAQ:MYGN) had its target price raised by TD Cowen from $4.50 to $6.75. TD Cowen currently has a hold rating on the stock.
NewAmsterdam Pharma (NASDAQ:NAMS) had its target price trimmed by Needham & Company LLC from $48.00 to $46.00. They currently have a buy rating on the stock.
Navient (NASDAQ:NAVI) had its target price reduced by TD Cowen from $8.50 to $8.00. TD Cowen currently has a sell rating on the stock.
Progyny (NASDAQ:PGNY) had its target price raised by Leerink Partners from $37.00 to $38.00. Leerink Partners currently has an outperform rating on the stock.
Insulet (NASDAQ:PODD) had its price target raised by Leerink Partners from $143.00 to $167.00. The firm currently has a market perform rating on the stock.
PROCEPT BioRobotics (NASDAQ:PRCT) had its price target boosted by Leerink Partners from $20.00 to $22.00. They currently have a market perform rating on the stock.
Qualcomm (NASDAQ:QCOM) had its target price cut by TD Cowen from $200.00 to $185.00. The firm currently has a buy rating on the stock.
Arcus Biosciences (NYSE:RCUS) had its target price increased by Leerink Partners from $46.00 to $49.00. They currently have an outperform rating on the stock.
Real REMAX Group (NASDAQ:REAX) had its price target reduced by BTIG Research from $35.00 to $25.00. BTIG Research currently has a buy rating on the stock.
Rapid7 (NASDAQ:RPD) had its price target raised by Royal Bank Of Canada from $12.00 to $16.00. Royal Bank Of Canada currently has a sector perform rating on the stock.
Rapid7 (NASDAQ:RPD) had its target price increased by Scotiabank from $10.15 to $14.50. Scotiabank currently has a sector perform rating on the stock.
Revolution Medicines (NASDAQ:RVMD) had its price target boosted by TD Cowen from $250.00 to $270.00. They currently have a buy rating on the stock.
Schrodinger (NASDAQ:SDGR) had its target price increased by TD Cowen from $31.00 to $36.00. The firm currently has a buy rating on the stock.
Sezzle (NASDAQ:SEZL) had its price target increased by TD Cowen from $160.00 to $200.00. The firm currently has a buy rating on the stock.
Silvaco Group (NASDAQ:SVCO) had its target price lowered by TD Cowen from $15.00 to $12.00. They currently have a buy rating on the stock.
Teads (NASDAQ:TEAD) had its target price reduced by Needham & Company LLC from $1.00 to $0.40. Needham & Company LLC currently has a buy rating on the stock.
Teva Pharmaceutical Industries (NYSE:TEVA) had its target price raised by Leerink Partners from $45.00 to $52.00. The firm currently has an outperform rating on the stock.
Travere Therapeutics (NASDAQ:TVTX) had its price target cut by Leerink Partners from $78.00 to $67.00. The firm currently has an outperform rating on the stock.
United Therapeutics (NASDAQ:UTHR) had its target price raised by TD Cowen from $675.00 to $700.00. TD Cowen currently has a buy rating on the stock.
United Therapeutics (NASDAQ:UTHR) had its target price increased by Royal Bank Of Canada from $697.00 to $725.00. The firm currently has an outperform rating on the stock.
Versigent (NYSE:VGNT) had its target price reduced by Royal Bank Of Canada from $53.00 to $52.00. Royal Bank Of Canada currently has an outperform rating on the stock.
Versigent (NYSE:VGNT) had its price target boosted by TD Cowen from $58.00 to $59.00. TD Cowen currently has a buy rating on the stock.
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by Leerink Partners from $50.00 to $54.00. They currently have an outperform rating on the stock.
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by Royal Bank Of Canada from $38.00 to $41.00. The firm currently has an outperform rating on the stock.
Wayfair (NYSE:W) had its target price boosted by Royal Bank Of Canada from $96.00 to $128.00. Royal Bank Of Canada currently has a sector perform rating on the stock.
Wayfair (NYSE:W) had its target price raised by TD Cowen from $110.00 to $114.00. TD Cowen currently has a hold rating on the stock.
Wolfspeed (NYSE:WOLF) had its target price cut by TD Cowen from $25.00 to $23.00. TD Cowen currently has a hold rating on the stock.
Zimmer Biomet (NYSE:ZBH) had its price target boosted by Royal Bank Of Canada from $110.00 to $125.00. The firm currently has an outperform rating on the stock.
Receive News & Ratings for Addus HomeCare Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
